Neosoma, Inc. — SEC Form D Filing

Neosoma, Inc. filed an SEC Form D on March 27, 2026, reporting $3.52M raised in Health Technology.

Form D filing details

Filing
SEC Form D
Filing date
March 27, 2026
Amount reported
$3.52M
Round stage
Seed
Industry
Health Technology
Website
https://www.neosomainc.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Clinicians often struggle to accurately assess brain lesions due to the complexity and variability in interpretation. Misjudgments can impact patient care and treatment decisions.

Solution

Neosoma provides a cloud software platform that automates lesion mapping and assessment, allowing for accurate tracking and quantification over time. This helps clinicians make informed decisions quickly.

Why now

The growing prevalence of neuro-oncological disorders and the increasing complexity of medical imaging require advanced tools for effective diagnosis and treatment planning.

Verdict

Investors said yes to Neosoma at that moment because they recognized the necessity for technological advancement in an increasingly complex healthcare landscape, betting implicitly on a significant shift in the diagnostic capability of clinicians via automation. This cleared because the platform's promise of precision and efficiency resonated, not because the market lack of competition in health technology was evident. However, the upside is limited given the challenges of regulatory compliance and the potential for rapid obsolescence due to technological advancements from larger incumbents.

Source: SEC EDGAR Form D filing